[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202092084A1 - Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения - Google Patents

Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения

Info

Publication number
EA202092084A1
EA202092084A1 EA202092084A EA202092084A EA202092084A1 EA 202092084 A1 EA202092084 A1 EA 202092084A1 EA 202092084 A EA202092084 A EA 202092084A EA 202092084 A EA202092084 A EA 202092084A EA 202092084 A1 EA202092084 A1 EA 202092084A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
agonists
differentiation
growth
methods
Prior art date
Application number
EA202092084A
Other languages
English (en)
Inventor
Малгорзата Доната Гонсиарз
Виктор Х. Обунгу
Ричард Тодд Пикард
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202092084A1 publication Critical patent/EA202092084A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В данном документе предложены соединения, которые вызывают потерю массы тела и лечат диабет, дислипидемию, НАСГ и/или ожирение. Также предложены фармацевтические композиции, содержащие такие соединения, и варианты терапевтического применения таких соединений и композиций, при этом такие соединения действуют как агонисты GDF15 с продленным временем действия и другими полезными свойствами.
EA202092084A 2018-04-06 2019-03-29 Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения EA202092084A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653759P 2018-04-06 2018-04-06
PCT/US2019/024756 WO2019195091A1 (en) 2018-04-06 2019-03-29 Growth differentiation factor 15 agonist compounds and methods of using the same

Publications (1)

Publication Number Publication Date
EA202092084A1 true EA202092084A1 (ru) 2021-01-27

Family

ID=66630339

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092084A EA202092084A1 (ru) 2018-04-06 2019-03-29 Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения

Country Status (29)

Country Link
US (1) US11104711B2 (ru)
EP (1) EP3774860B1 (ru)
JP (1) JP7064618B2 (ru)
KR (1) KR102501922B1 (ru)
CN (1) CN112004821B (ru)
AR (1) AR115021A1 (ru)
AU (1) AU2019248535B2 (ru)
BR (1) BR112020017256A2 (ru)
CA (1) CA3096375C (ru)
CL (1) CL2020002564A1 (ru)
CO (1) CO2020012403A2 (ru)
CR (1) CR20200454A (ru)
DO (1) DOP2020000157A (ru)
EA (1) EA202092084A1 (ru)
EC (1) ECSP20062930A (ru)
ES (1) ES2937049T3 (ru)
IL (1) IL276980A (ru)
JO (1) JOP20200252B1 (ru)
MA (1) MA52228A (ru)
MX (1) MX2020010370A (ru)
NZ (1) NZ767242A (ru)
PE (1) PE20212133A1 (ru)
PH (1) PH12020551656A1 (ru)
SA (1) SA520420287B1 (ru)
SG (1) SG11202009853VA (ru)
TW (1) TWI724392B (ru)
UA (1) UA127545C2 (ru)
WO (1) WO2019195091A1 (ru)
ZA (1) ZA202005385B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103533951B (zh) 2011-04-08 2017-04-19 安姆根有限公司 使用生长分化因子15(gdf‑15)治疗或改善代谢障碍的方法
KR20240000642A (ko) 2013-07-31 2024-01-02 암젠 인크 성장 분화 인자 15(gdf-15) 작제물
EA202092419A1 (ru) 2018-04-09 2021-02-05 Эмджен Инк. Слитые белки ростового фактора дифференцировки 15
EP4041281A1 (en) 2019-10-04 2022-08-17 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
US20240350588A1 (en) 2021-08-24 2024-10-24 Sunshine Lake Pharma Co., Ltd. Gdf15 fusion proteins and use thereof
WO2023125881A1 (zh) 2021-12-31 2023-07-06 广东东阳光药业有限公司 Glp-1和gdf15的融合蛋白及其用途
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN118580334A (zh) * 2023-03-03 2024-09-03 北京志道生物科技有限公司 一种多肽分子

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
BR112012029577B1 (pt) * 2010-05-21 2022-04-12 Xl-Protein Gmbh Conjugado de fármaco compreendendo polipeptídeos helicoidais randômicos prolina/alanina biossintéticos, e composição farmacêutica ou diagnóstica
DK2670847T3 (en) * 2011-02-03 2017-01-16 Xoma Technology Ltd Methods and Materials for Improving Functional Protein Expression in Bacteria
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
ES2791183T3 (es) * 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
KR20240000642A (ko) 2013-07-31 2024-01-02 암젠 인크 성장 분화 인자 15(gdf-15) 작제물
KR20230141929A (ko) 2013-07-31 2023-10-10 암젠 인크 Fc-함유 폴리펩타이드의 안정화
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
WO2015198199A1 (en) 2014-06-23 2015-12-30 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof.
EP3160496B1 (en) 2014-06-24 2021-03-03 Novo Nordisk As MIC-1 FUSION PROTEINS AND RELATED USES
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2015339134B2 (en) 2014-10-30 2021-06-17 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
DK3212226T3 (da) * 2014-10-31 2020-06-15 Ngm Biopharmaceuticals Inc Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
KR20170134542A (ko) 2015-04-02 2017-12-06 얀센 바이오테크 인코포레이티드 프로톡신-ii 변이체 및 사용 방법
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法
WO2017121865A1 (en) 2016-01-15 2017-07-20 Novo Nordisk A/S Mic-1 receptor and uses thereof
CN108697795A (zh) 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
EP3413620A4 (en) 2016-02-29 2019-01-16 Huawei Technologies Co., Ltd. VIDEO OPTIMIZATION PROCEDURE, USER DEVICE UNIT AND NETWORK DEVICE UNIT
JP2019513224A (ja) 2016-03-04 2019-05-23 エヌジーエム バイオファーマシューティカルス,インコー 体重を調節するための組成物及び方法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof

Also Published As

Publication number Publication date
CL2020002564A1 (es) 2021-01-29
CN112004821B (zh) 2024-01-02
US11104711B2 (en) 2021-08-31
UA127545C2 (uk) 2023-10-04
CO2020012403A2 (es) 2020-10-30
KR102501922B1 (ko) 2023-02-23
PH12020551656A1 (en) 2021-07-26
IL276980A (en) 2020-10-29
SG11202009853VA (en) 2020-11-27
ZA202005385B (en) 2022-09-28
EP3774860B1 (en) 2022-12-28
CA3096375C (en) 2023-09-12
US20190309033A1 (en) 2019-10-10
EP3774860A1 (en) 2021-02-17
DOP2020000157A (es) 2020-09-15
AR115021A1 (es) 2020-11-18
WO2019195091A1 (en) 2019-10-10
JOP20200252A1 (ar) 2020-10-04
KR20200128091A (ko) 2020-11-11
BR112020017256A2 (pt) 2020-12-22
CR20200454A (es) 2020-11-18
MX2020010370A (es) 2021-01-08
NZ767242A (en) 2024-07-05
JOP20200252B1 (ar) 2023-09-17
SA520420287B1 (ar) 2024-03-17
TW201946661A (zh) 2019-12-16
ECSP20062930A (es) 2020-11-30
PE20212133A1 (es) 2021-11-05
JP7064618B2 (ja) 2022-05-10
CN112004821A (zh) 2020-11-27
ES2937049T3 (es) 2023-03-23
AU2019248535B2 (en) 2021-09-02
MA52228A (fr) 2021-02-17
AU2019248535A1 (en) 2020-09-10
TWI724392B (zh) 2021-04-11
JP2021517584A (ja) 2021-07-26
CA3096375A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
EA202092084A1 (ru) Соединения - агонисты фактора роста и дифференцировки 15 и способы их применения
MX2019003790A (es) Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA202090448A1 (ru) Дигидрооксадиазиноны
EA201692007A1 (ru) Соединения изоиндолинона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
ZA202104594B (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
EA202090414A1 (ru) Соединения и их применение
NZ734400A (en) Amide compounds as 5-ht4 receptor agonists
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201991898A1 (ru) Двойные ингибиторы magl и faah
EA201991112A1 (ru) Композиции и способы, связанные с пиридиноилпиперидиновыми агонистами 5-ht1f
ZA202005083B (en) Solid forms of fasoracetam
EA201800565A1 (ru) Композиция для лечения заболеваний уха, содержащая (+)-азасетрон
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.
EA201991395A1 (ru) Новые композиции для лечения суставных нарушений
EA202191294A1 (ru) Олигосахаридные композиции и способы их применения
MX2021000475A (es) Isoxazol como agonista del receptor fxr.
EA202191103A1 (ru) Терапевтические соединения